Efficacy, safety, and biomarker analysis of neoadjuvant camrelizumab plus apatinib as a chemotherapy-free strategy for early-stage triple-negative breast cancer: a phase II study.
Breast Cancer Res TreatAug 31, 2026 (epub)
Zhenluan Tian, Hengyu Li, Yuxin Deng et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase II clinical trial evaluated the efficacy and safety of neoadjuvant camrelizumab plus apatinib in patients with early-stage triple-negative breast cancer (TNBC) and high tumor-infiltrating lymphocytes (TILs). Among 11 patients who underwent surgery, the pathological complete response (pCR) rate was 27.3%, and the objective response rate (ORR) was 46.2%.
Key findings
- The pathological complete response (pCR) rate was 27.3% (3/11) among patients who underwent surgery.
- The objective response rate (ORR) was 46.2% (6/13) in evaluable patients.
- The 24-month disease-free survival (DFS) rate was 90.9%.
- Treatment-related adverse events (TRAEs) were mostly grade 1-2, with 28.6% experiencing grade ≥3 events.
Why it matters
This study presents a potential chemotherapy-free treatment option for early-stage TNBC, which may reduce toxicity while maintaining efficacy. Understanding the role of immune checkpoint inhibitors and anti-angiogenic agents could influence future treatment strategies.